Verona Pharma Prices Lung Disease Therapy Above Expectations at US$ 2,950/ month

PHARMACY - HEALTH - Verona Pharma said on Thursday its therapy for a chronic and potentially fatal lung disease will have a wholesale price of US$ 2,950 per month, above the estimated cost-effectiveness range by a drug-pricing watchdog.

The U.S. health regulator's assent on Wednesday for the therapy, branded as Ohtuvayre, gives patients with chronic obstructive pulmonary disease (COPD) a new inhalable, non-steroid treatment.

Read Also: Oil Prices Extend Upward Momentum on Expectations of Tighter Supply